Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven non-Hodgkin's disease that has failed both prior high-dose chemotherapy and bone marrow transplantation~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC greater than 2,000/mm\^3~* Platelet count greater than 20,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~Renal:~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No serious active infections~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulatory agents (e.g., interferon or interleukin-2)~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~Endocrine therapy:~* At least 4 weeks since prior corticosteroids~* No concurrent corticosteroids~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Not specified~Other:~* No prior antineoplaston therapy~* No other concurrent antineoplastic agents~* No concurrent antibiotics, antifungals, or antivirals

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).